the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Bladder Cancer Clinical Trials
Interventional only

Phase II
Study No PI Title
IRB18-0328 O'Donnell, Peter Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Details
IRB18-0160 Sweis, Randy A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer Details
IRB18-0188 Sweis, Randy An international, multi-center, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in patients with FGFR-positive locally advanced inoperable or metastatic urothelial carcinoma Details
IRB17-0863 O'Donnell, Peter A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy Details
IRB16-0787 O'Donnell, Peter A Phase II Trial of MK3475 in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB13-0540 O'Donnell, Peter Afatinib in Advanced Refractory Urothelial Cancer Details
Phase I
Study No PI Title
IRB18-0188 Sweis, Randy An international, multi-center, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in patients with FGFR-positive locally advanced inoperable or metastatic urothelial carcinoma Details
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1544 Steinberg, Gary A Phase Ib, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder Details
IRB15-1130 Chmura, Steven Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
Others
Study No PI Title
IRB16-0355 O'Donnell, Peter UC-GENOME: Urothelial Cancer-GENOmic analysis to iMprove patient outcomes and rEsearch Details
15550B Steinberg, Gary Bladder Cancer Sample Collection
12278A Steinberg, Gary Clinical Urology Research Screening Protocol


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .